VACBF (Nykode Therapeutics AS) Asset Turnover: 0.00 (As of Mar. 2026)


VACBF Nykode Therapeutics AS VACBF
28 GF Score
Price $0.32
GF Value $0.76
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Asset Turnover?

Nykode Therapeutics AS VACBF -1.05% 28 Asset Turnover is 0.00 as of Mar. 2026. GuruFocus rates VACBF with a GF Score™ of 28/100 and a GF Value™ of $0.76 (Possible Value Trap). The stock has 2 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Nykode Therapeutics AS's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Nykode Therapeutics AS's Total Assets for the quarter that ended in Mar. 2026 was $96.91 Mil. Therefore, Nykode Therapeutics AS's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Nykode Therapeutics AS's annualized ROE % for the quarter that ended in Mar. 2026 was -18.38%. It is also linked to ROA % through Du Pont Formula. Nykode Therapeutics AS's annualized ROA % for the quarter that ended in Mar. 2026 was -16.98%.

Nykode Therapeutics AS  (OTCPK:VACBF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Nykode Therapeutics AS's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-16.452/89.525
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-16.452 / 0)*(0 / 96.9115)*(96.9115/ 89.525)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0825
=ROA %*Equity Multiplier
=-16.98 %*1.0825
=-18.38 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Nykode Therapeutics AS's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-16.452/96.9115
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-16.452 / 0)*(0 / 96.9115)
=Net Margin %*Asset Turnover
= %*0
=-16.98 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Nykode Therapeutics AS Asset Turnover Related Terms

Nykode Therapeutics AS Asset Turnover Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Asset Turnover Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only 0.14 0.03 0.06 0.05 0.00

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VACBF vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, Nykode Therapeutics AS's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nykode Therapeutics AS Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's Asset Turnover falls into.


VACBF
28GF Score
Nykode Therapeutics AS VACBF
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Nykode Therapeutics AS's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=0/( (153.481+99.955)/ 2 )
=0/126.718
=0.00

Nykode Therapeutics AS's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (99.955+93.868)/ 2 )
=0/96.9115
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.00 mean?
Nykode Therapeutics AS (VACBF) has a Asset Turnover of 0.00 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Asset Turnover too high?
Nykode Therapeutics AS's current Asset Turnover is 0.00. Overall, Nykode Therapeutics AS has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Asset Turnover compare to VRTX and REGN?
Nykode Therapeutics AS's Asset Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Asset Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.76, compared to a current price of $0.32 — trading 57.7% below its estimated fair value. The current Asset Turnover is 0.00. Nykode Therapeutics AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Asset Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of $0.32 is trading 57.7% below its estimated GF Value™ of $0.76. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for VACBF:

  • Asset Turnover: 0.00
  • GF Value™: $0.76 vs. price of $0.32 (57.7% below fair value)
  • GF Score™: 28/100 with 2 warning signs

No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
28GF Score

Get the complete analysis for VACBF

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price
$0.76
GF Value